Abstract
Advances in understanding the biomolecular basis of the disease's inflammatory and remodeling responses are offering new therapeutic choices—and sometimes new drugdelivery system∼n categories such as B-agonists, glucocorticoids, and leukotriene blockers. Meanwhile, researchers are exploring novel targets, including intercellular signals and cell-adhesion and gene-activating molecules.